Radformation, Inc., a company renowned for its automation solutions in cancer care, has recently acquired Limbus AI, a leading provider of automated contouring software for radiation therapy. This acquisition marks Radformation’s commitment to innovation and expanding its AI-driven capabilities in cancer treatment.
Kurt Sysock, CEO of Radformation, emphasized the company’s goal of improving the radiation therapy process through efficiency, quality, and patient safety. By integrating Limbus’ technology and expertise into their offerings, Radformation aims to push the boundaries of innovative software solutions in radiation therapy even further.
The merger of Radformation and Limbus AI seeks to combine the strengths of both companies’ platforms, resulting in the most advanced AI-driven contouring solution currently available. This collaboration is expected to not only enhance contouring capabilities but also drive innovation, leading to new advancements in radiation therapy.
Karl Otto, CEO of Limbus AI, highlighted the shared vision of both companies in delivering innovative software solutions for patient care. The merger will leverage the talents of both teams to achieve significant progress in the field of radiation therapy.
By combining Radformation’s global presence and extensive product utilization with Limbus AI’s impact on numerous patients worldwide, this acquisition aims to accelerate innovation, extend reach, and improve patient outcomes on a global scale. This collaboration signifies a new era in healthcare technology with the potential to revolutionize cancer care. For more information visit www.radformation.com
